Interactive Features

Quiz

Non-JAK-Inhibitor Agents for Myelofibrosis

12/05/2023

____ is a non-JAK-inhibitor agent that has shown promise in the treatment landscape of myelofibrosis.

____ is a non-JAK-inhibitor...

12/05/2023

Oncology

Quiz

JAK Inhibitor Momelotinib for Myelofibrosis

11/28/2023

True or False: Results of the MOMENTUM study indicated that momelotinib showed benefits in symptom improvement, spleen improvement, and anemia among patients with myelofibrosis.

True or False: Results of the...

11/28/2023

Oncology

Quiz

Treating Myelofibrosis With Low-Dose Splenic Radiotherapy

11/28/2023

True or False: According to a retrospective institutional review, low-dose splenic radiotherapy in combination with allogeneic hematopoietic stem cell transplantation improved symptoms of splenomegaly and had encouraging safety outcomes among...

True or False: According to a...

11/28/2023

Oncology

Quiz

Quiz: BMS-986158 Plus Ruxolitinib or Fedratinib as Combination Treatment for Myelofibrosis

03/13/2023

True or False: In a study evaluating the safety and efficacy of BMS-986158 plus JAK inhibitors ruxolitinib or fedratinib for myelofibrosis, no serious treatment-related adverse events led to treatment discontinuation among patients who...

True or False: In a study...

03/13/2023

Oncology

Quiz

Quiz: Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Previously Treated With a JAK Inhibitor

12/07/2022

True or false: Momelotinib improved symptom responses, transfusion requirements, and spleen responses in symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol with comparable safety...

True or false: Momelotinib...

12/07/2022

Oncology

Quiz

Quiz: Total Symptom Score of Momelotinib vs Danazol in Patients With Myelofibrosis

11/08/2022

Quiz: Momelotinib was found to be superior to danazol in patients with symptomatic, anemic, and thrombocytopenic myelofibrosis for symptom responses, according to a phase 3 trial. What was the total symptom score response rate with...

Quiz: Momelotinib was found to...

11/08/2022

Oncology

Quiz

Tolerability of Jaktinib in JAK Inhibitor-Naïve Patients with Myelofibrosis

10/05/2022

True or False: According to a recent study, jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis.

True or False: According to a...

10/05/2022

Oncology

Quiz

Quiz: Red Blood Cell Transfusion During Treatment of Myelofibrosis With Ruxolitinib

09/02/2022

According to a multicenter study, red blood cell transfusion is often required during treatment of myelofibrosis with ruxolitinib, particularly among those who underwent ≥ 2 units of red blood cell transfusion over how many weeks?

According to a multicenter...

09/02/2022

Oncology

Quiz

Quiz: Do Features of Atypical Myeloproliferative Disorder Differ?

03/22/2022

True or false: A retrospective cohort study found that features of patients with atypical myeloproliferative disorder differed markedly from those of patients with pre-PMF.

True or false: A retrospective...

03/22/2022

Oncology

Quiz

Quiz: Sotatercept for Anemic Patients With MPN-Associated MF

01/20/2022

True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.

True or false: A phase 2 study...

01/20/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology